Accordingly, the CEO of Saman Daroo 8, Dr Seyyed Ahmad Mohajeri, along with a group of deputies and managers from the pharmaceutical company, sat for talks with top managers from an outstanding Sri Lankan bio-tech pharmaceutical distribution company in the northeastern Iranian city of Mashhad.
In the meeting, the two sides agreed on joint projects to export Factor VIII (FVIII) product of Saman Daroo 8, which operates under Endowment Beneficiary Foundation of Imam Reza shrine.
Also, the number of patients in need of FVIII in Sri Lanka, ways for cooperation, marketing and sales, financial issues, and required resources to register the company and its product in Sri Lankan Health Ministry have been discussed.
A contract has also been signed between the two sides to establish a registered sales office for FVIII in Sri Lanka under the brand name Safacto.
The two sides set their sights on increasing the export of Saman Daroo 8 products to the South Asian country. Moreover, prospects for exporting other pharmaceutical products such as Infliximab and Ustekinumab have been weighed. 
Established in 1998, Saman Daroo has held negotiations with other regional countries as well to supply demands for the knowledge-based FVIII medicine in the Middle East and the Commonwealth of Independent States (CIS).